Humanigen chosen by National Institute of Health's upcoming coronavirus clinical trial

2
Поделиться
Скопировать ссылку

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of …